Search Results for “acquisition” – Page 41 – media

AstraZeneca’s Three-in-One COPD Inhaler Succeeds in Phase III Trial

AstraZeneca has GlaxoSmithKline and its chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta squarely in its sights. This morning, AstraZeneca revealed Phase III data that shows its experimental three-in-one inhaler PT010 improved lung function in patients.
- Source: Biospace
- 586
- January 29, 2018
Clinical Trials COPD inhaler
Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer

Celgene agreed on Monday to buy the rest of Juno Therapeutics it doesn't already own for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
- Source: Cnbc
- 982
- January 24, 2018
cancer CAR–T Market Views
AI funding tops $1 billion mark as mobile investments wane

Health IT funding set a record in 2017 with AI and predictive analytics as top tech funded, with patient engagement, telehealth and clinical decision support close behind.
- Source: Healthcare IT News
- 836
- January 19, 2018
AI digital health healthcare technology Market Views
EU nod for Shire’s longer-acting haemophilia A therapy

Shire’s Adynovi has been approved for use in Europe for on-demand and prophylactic use in patients 12 years and older with the rare bleeding disorder haemophilia A.
- Source: Pharmatimes
- 534
- January 18, 2018
Adynovi haemophilia A New Approvals
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies

Celgene Corporation (CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.
- Source: finance.yahoo
- 510
- January 12, 2018
Celgene FDA Fedratinib Impact Market Views myelofibrosis
Busy Takeda Takes Out Tigenix in $630M Deal

Shares of Belgium-based TiGenix NV shot up more than 72 percent in pre-market trading after Japan’s Takeda Pharmaceuticals opted to acquire the company with which it has a developmental partnership for $630 million.
- Source: Biospace
- 513
- January 9, 2018
Market Views pharmaceutical company stem cells
In boost to Abbott, spinal-cord implants emerge as alternative to pills

Recent innovations from global device makers like Abbott to smaller specialists such as Nevro Corp. made the implants more powerful and effective. Combined with a national crackdown on narcotics and wanton pain pill prescriptions, they are spurring demand for implants.
- Source: Crain's Chicago Business
- 562
- January 4, 2018
Abbott Company Insight healthcare technology medtech nerve cell opioid
Artificial Intelligence Could Help in Breast Cancer Diagnosis

Researchers say AI procedure was successful in detecting the spread of breast cancer. It’s the latest artificial intelligence innovation in the medical world.
- Source: healthline
- 650
- December 19, 2017
Artificial Intelligence breast cancer Researches
LSP closes $330M medtech fund, plots 15 investments

LSP has raised $330 million for its second medical technology fund. The big jump in size over the first fund tees up LSP to place bets on 15 companies with close-to-market devices, diagnostics and digital health tools.
- Source: fiercebiotech
- 684
- December 14, 2017
Company Insight diagnostics digital health
Gilead Sciences to Acquire Cell Design Labs for $567 Million

Gilead Sciences, Inc. GILD and its newly acquired cell therapy subsidiary -Kite Pharma- announced that they have inked an agreement to acquire Cell Design Labs, Inc. for $567 million. Gilead will also acquire 12.2% of Cell Design shares which are owned by Kite Pharma.
- Source: qc.nasdaq
- 429
- December 11, 2017

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.